A study on the markers of early kidney damage in patients with gout


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To examine markers of kidney damage kim-1 and VEGF-A using ELISA and flow flowmetry in gout patients with and without symptoms of CKD. Materials and methods. The study involved 80 patients with primary gout without the history of diabetes. The control group comprised 37 healthy volunteers matched by age, without risk factors for CKD and signs of kidney damage, metabolic syndrome, hypertension and hyperuricemia. Testing of VEGF-A and a KIM-1 was conducted in the serum and urine by ELISA and flow flowmetry. Results. Gout patients without signs of CKD as compared with the control group had a significantly lower levels of VEGF-A by both Elisa (p=0.02) and flow flowmetry (p=0.002). The lowest levels were found among patients without manifesting CKD as compared to the control group and the gout patients with CKD. There was an inverse correlation between VEGF-A and the level of hyperuricemia (Rs=-0.56, p=0.00005). In patients with gout urinary excretion of KIM-1 was significantly greater compared with healthy volunteers (p=0.003), with the highest concentrations in gout patients without clinically evident CKD (p=0.01). No correlation was found between urinary KIM-1 and clinical, laboratory and diagnostic testing characteristics. Serum levels of the markers were not significantly different. Conclusion. Low levels of urinary VEGF-A and high levels of urinary KIM-1 in patients with gout without CKD symptoms may indicate developing endothelial dysfunction and tubulointerstitial damage. These findings suggest that VEGF-A KIM-1 could be the promising markers for early diagnosis of kidney damage in patients with gout. Urinary levels of VEGF-A can be determined both by ELISA, and flow flowmetry.

Full Text

Restricted Access

About the authors

L. I Urazaeva

Email: ulil@bk.ru

A. N Maksudova

References

  1. Fine L.G., Bandyopadhay D., Norman J.T. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int. Suppl. 2000; 75: 22-26.
  2. Johnson R.J., Kang D.H., Feig D., Kivlighn S., Kanellis J., Watanabe S., Tuttle K.R., Rodriguez-Iturbe B., Herrera-Acosta J., Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease. Hypertension. 2003; 41: 1183-1190.
  3. Feig D.I., Mazzali M., Kang D.H., Nakagawa T., Price K., Kannelis J., Johnson R.J. Serum uric acid: A risk factor and a target for treatment. J. Am. Soc. Nephrol. 2006; 17: 69-73.
  4. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008;359:1811-1121.
  5. Numa S., Hirai T., Nakagawa K., Ohara K., Fukuda N., Nozawa T., Inoue H. Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically lowintermediate risk. Circ. J. 2014; 78: 1600-1605.
  6. Causevic A., Semiz S., Macic Dzankovic A., Cico B., Dujic T., Malenica M., Bego T. Relevance of uric Acid in progression of type 2 diabetes mellitus. Bosn. J. Basic Med. Sci. 2010;10:54-59.
  7. Бобкова И.Н. Клиническое значение определения в моче маркеров эндотелиальной дисфункции и факторов ангиогенеза в оценке тубулоинтерстициального фиброза при хроническом гломерулонефрите. Тер. архив. 2007; 6: 10-15.
  8. Shulman K., Rosen S., Tognazzi K., Manseau E.J., Brown L.F. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J. Am. Soc. Nephrol. 1996;7:661-666.
  9. Brown L.F., Berse B., Tognazzi K., Manseau E.J., Van de Water L., Senger D.R., Dvorak H.F., Rosen S. Vascular permeability factor mRNA andprotein expression in human kidney. Kidney Int. 1992; 42: 1457-1461.
  10. Schrijvers B.F., Flyvbjerg A., De Vriese A.S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004; 65:2003-2017.
  11. Femke Waanders M.D., Vaidya V.S., van Goor H., Leuvenink H., Damman K., Hamming I., Bonventre J.V., Vogt L., Navis G. Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled Trial. Am. J. Kidney Dis. 2009; 53: 16-25.
  12. Jungbauer C.G., Birner C., Jung B., Buchner S., Lubnow M., von Bary C., Endemann D., Banas B., Mack M., Böger C.A., Riegger G., Luchner A. Kidney injury molecule-1 and N-acetyl-ß-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur. J. Heart Fail. 2011; 13: 1104-1110.
  13. Nauta F.L., Boertien W.E., Bakker S.J.L., van Goor H., van Oeveren W., de Jong P.E., Bilo H., Gansevoort R.T. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011; 34: 975-981.
  14. Mohammadi-Karakani A., Asgharzadeh-Haghighi S., Ghazi-Khansari M., Hosseini R. Determination of urinary enzymes as a marker of early renal damage in diabetic patients. J. Clin. Lab. Anal. 2007; 21: 413-417.
  15. Bolignano D., Lacquaniti A., Coppolino G., Donato V., Fazio M.R., Nicocia G., Buemi M. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res. 2009;32:91-98.
  16. Uslu S., Efe B, Alatasx O., Kebapçi N., Colak O., Demirüstü C., Yörük A. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J. Nephrol. 2005; 18: 559-567.
  17. Fu W.J., Xiong S.L., Fang Y.G., Wen S., Chen M.L., Deng R.T., Zheng L., Wang S.B., Pen L.F., Wang Q. Fang Urinary tubular biomarkers in shortterm type 2 diabetes mellitus patients: a cross-sectional study. Endocrine. 2012; 41: 82-88.
  18. Kim S.S., Song S.H., Kim I.J., Yang J.Y., Lee J.G., Kwak I.S., Kim Y.K. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res. Clin. Pract. 2012; 251-257.
  19. Brott D.A., Furlong S.T., Adler S.H., Hainer J.W., Arani R.B., Pinches M., Rossing P., Chaturvedi N.; DIRECT Programme Steering Committee. Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. Drug Des. Devel. Ther. 2015; 9: 3191-3198.
  20. Rudnicki M., Perco P., Enrich J., Eder S., Heininger D., Bernthaler A., Wiesinger M., Sarközi R., Noppert S.J., Schramek H., Mayer B., Oberbauer R., Mayer G. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab. Invest. 2009; 89: 337-346.
  21. Schrijvers B.F., Flyvbjerg A., De Vriese A.S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004; 65: 2003-2017.
  22. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.P., Kikkawa Y., Miner J.H., Quaggin S.E. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 2003; 111: 707-716.
  23. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 2007; 49: 186-193.
  24. Basile D.P., Friedrich K., Chelladurai B., Leonard E.C., Parrish A.R. Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am. J. Physiol. Renal. Physiol. 2008; 294: 928-936.
  25. Chung A.W., Hsiang Y.N., Matzke L.A., McManus B.M., van Breemen C., Okon E.B. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ. Res. 2006; 99: 140-148.
  26. Lindenmeyer M.T., Kretzler M., Boucherot A., Berra S., Yasuda Y., Henger A., Eichinger F., Gaiser S., Schmid H., Rastaldi M.P., Schrier R.W., Schlöndorff D., Cohen C.D. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J. Am. Soc. Nephrol. 2007; 18: 1765-1776.
  27. Nauta F.L., Boertien W.E., Bakker S.J.L., van Goor H., van Oeveren W., de Jong P.E., Bilo H., Gansevoort R.T. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011; 34: 975-981.
  28. Fu W.J., Xiong S.L., Fang Y.G., Wen S., Chen M.L., Deng R.T., Zheng L., Wang S.B., Pen L.F., Wang Q. Fang Urinary tubular biomarkers in shortterm type 2 diabetes mellitus patients: a cross-sectional study. Endocrine. 2012; 41: 82-88.
  29. Lindenmeyer M.T., Kretzler M., Boucherot A., Berra S., Yasuda Y., Henger A., Eichinger F., Gaiser S., Schmid H., Rastaldi M.P., Schrier R.W., Schlöndorff D., Cohen C.D. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J. Am. Soc. Nephrol. 2007; 18: 1765-1776.
  30. Rudnicki M., Perco P., Enrich J., Eder S., Heininger D., Bernthaler A., Wiesinger M., Sarközi R., Noppert S.J., Schramek H., Mayer B., Oberbauer R., Mayer G. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab. Invest. 2009; 89: 337-346.
  31. Mazali F.C., Johnson R.J., Mazzali M. Use of uric acid-lowering agents limits experimental cyclosporine nephropathy. Nephron. Exp. Nephrol. 2012; 120: 12-19.
  32. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., Krotova K., Block E.R., Prabhakar S., Johnson R.J. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005; 67: 1739-1742.
  33. Kang D.H., Nakagawa T., Feng L., Watanabe S., Han L., Mazzali M., Truong L., Harris R., Johnson R.J. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 2002; 13: 2888-2897.
  34. Iseki K., Ikemyia Y., Inoue T., Iseki C., Kinjo K., Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am. J. Kidney Dis. 2004; 44: 642-650.
  35. Ruilope L.M., Garcia-Puig J. Hyperuricemia and renal function. Curr. Hypertens Rep. 2001; 3: 197-202.
  36. Short R.A., Johnson R.J., Tuttle K.R. Uric acid, microalbuminuria and cardiovascular events in high risk patients. Am. J. Nephrol. 2005; 25: 36-44.
  37. Yu S., Hong Q., Wang Y., Hou K., Wang L., Zhang Y., Fu B., Zhou Y., Zheng W., Chen X., Wu D. High Concentrations of Uric Acid Inhibit Angiogenesis via Regulation of the Krüppel-Like Factor 2-Vascular Endothelial Growth Factor-A Axis by miR-92a. Circ. J. 2015; 79: 2487-2498.
  38. Вербовой А.Ф., Цанава И.А., Вербовая Н.И. Адипокины и гормональнометаболические показатели у больных сахарным диабетом 2 типа и подагрой. Фарматека. 2015; 17: 50-54.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download